TABLE OF CONTENTS
1 INTRODUCTION 47
1.1 OBJECTIVES OF THE STUDY 47
1.2 MARKET DEFINITION 47
1.3 OVERVIEW OF THE NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET 47
1.4 LIMITATIONS 50
1.5 MARKETS COVERED 50
2 MARKET SEGMENTATION 53
2.1 MARKETS COVERED 53
2.2 GEOGRAPHICAL SCOPE 54
2.3 YEARS CONSIDERED FOR THE STUDY 55
2.4 CURRENCY AND PRICING 55
2.5 DBMR TRIPOD DATA VALIDATION MODEL 56
2.6 MULTIVARIATE MODELLING 59
2.7 PRODUCT TYPE LIFELINE CURVE 59
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 60
2.9 DBMR MARKET POSITION GRID 61
2.10 VENDOR SHARE ANALYSIS 62
2.11 MARKET END COVERAGE GRID 63
2.12 SECONDARY SOURCES 64
2.13 ASSUMPTIONS 64
3 EXECUTIVE SUMMARY 65
4 PREMIUM INSIGHT 68
4.1 PESTEL'S MODEL 69
4.2 PORTER'S 5 FORCES 70
4.3 EPIDEMIOLOGY 71
4.4 BRAND ANALYSIS 72
4.5 ROLE OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML): NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET 76
4.6 INDUSTRY INSIGHTS: 78
5 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, REGULATORY 79
5.1 NORTH AMERICA 79
5.1.1 REGULATORY SCENARIO IN THE U.S 79
6 MARKET OVERVIEW 81
6.1 DRIVERS 83
6.1.1 INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMOURS, LYMPHOMA, AND ADENOCARCINOMA 83
6.1.2 RISE IN ALCOHOL CONSUMPTION AND SURGE IN SMOKING 83
6.1.3 INCREASE IN THE GERIATRIC POPULATION 84
6.1.4 RECENT ADVANCEMENTS IN GASTRIC CANCER DIAGNOSTICS PRODUCTS 84
6.2 RESTRAINTS 85
6.2.1 HIGH COST OF GASTRIC CANCER DIAGNOSTIC TEST 85
6.2.2 LACK OF SUFFICIENT FINANCIAL SUPPORT FROM HEALTH INSURANCE POLICIES 85
6.3 OPPORTUNITIES 86
6.3.1 RISE IN THE ADOPTION OF AUTOMATED SYSTEMS 86
6.3.2 INCREASED RESEARCH AND DEVELOPMENT ON CANCER DIAGNOSTICS PRODUCTS 86
6.3.3 STRATEGIC INITIATIVES BY EMERGING PLAYERS 87
6.4 CHALLENGES 88
6.4.1 STRINGENT REGULATIONS AND POLICIES FOR APPROVING THE COMPLICATED NATURE OF RADIATION DEVICES 88
6.4.2 LIMITATIONS OF RADIATION TESTS 88
7 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 89
7.1 OVERVIEW 90
7.2 REAGENTS & CONSUMABLES 93
7.2.1 KITS 94
7.2.1.1 DNA POLYMERASE KITS 94
7.2.1.2 PCR KITS 94
7.2.1.3 NUCLEIC ACID ISOLATION KITS 94
7.2.1.4 OTHERS 94
7.2.2 REAGENTS 95
7.2.2.1 ASSAYS 95
7.2.2.2 BUFFERS 95
7.2.2.3 PRIMERS 95
7.2.2.4 OTHERS 95
7.3 INSTRUMENTS 96
7.4 SERVICES 97
8 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE 98
8.1 OVERVIEW 99
8.2 CONFIRMATORY TEST 102
8.2.1 IMAGING TESTS 103
8.2.1.1 PET SCAN/CT SCAN 103
8.2.1.2 CT SCAN 103
8.2.1.3 ULTRASOUND 103
8.2.1.4 MRI 104
8.2.1.5 X-RAY 104
8.2.2 BIOMARKER 104
8.2.2.1 DNA BIOMARKER 104
8.2.2.2 RNA BIOMARKER 104
8.2.2.3 PROTEIN BIOMARKER 104
8.2.3 BIOPSY 104
8.3 GASTRIC CANCER SCREENING TESTS/PHYSICAL EXAM 105
9 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP 106
9.1 OVERVIEW 107
9.2 GERIATRICS 110
9.3 ADULT 111
9.4 PEDIATRIC 112
10 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE 113
10.1 OVERVIEW 114
10.2 INTESTINAL OR DIFFUSE ADENOCARCINOMA 117
10.3 CARCINOID TUMOR 118
10.4 GASTROINTESTINAL STROMAL TUMOR 119
10.5 GASTRIC LYMPHOMA 120
10.6 OTHERS 121
11 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE 122
11.1 OVERVIEW 123
11.2 STAGE I 126
11.2.1 STAGE IA 127
11.2.2 STAGE IB 127
11.3 STAGE II 127
11.3.1 STAGE IIA 128
11.3.2 STAGE IIB 128
11.4 STAGE III 128
11.4.1 STAGE IIIA 129
11.4.2 STAGE IIIB 130
11.4.3 STAGE IIIC 130
11.5 STAGE 0 130
12 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER 131
12.1 OVERVIEW 132
12.2 MALE 135
12.3 FEMALE 136
13 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE 137
13.1 OVERVIEW 138
13.2 STOOL 141
13.3 TISSUE 142
13.4 BLOOD 143
13.5 URINE 144
14 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER 145
14.1 OVERVIEW 146
14.2 HOSPITALS 149
14.3 DIAGNOSTIC LABORATORIES 150
14.4 CANCER RESEARCH INSTITUTES 151
14.5 ONCOLOGY SPECIALTY CLINICS 152
14.6 OTHERS 153
15 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 154
15.1 OVERVIEW 155
15.2 DIRECT TENDERS 158
15.3 RETAIL SALES 159
16 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION 160
16.1 NORTH AMERICA 161
16.1.1 U.S. 171
16.1.2 CANADA 176
16.1.3 MEXICO 181
17 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 186
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 186
18 SWOT ANALYSIS 187
19 COMPANY PROFILE 188
19.1 F. HOFFMANN-LA ROCHE LTD 188
19.1.1 COMPANY SNAPSHOT 188
19.1.2 REVENUE ANALYSIS 188
19.1.3 COMPANY SHARE ANALYSIS 189
19.1.4 PRODUCT PORTFOLIO 189
19.1.5 RECENT DEVELOPMENT 189
19.2 GENERAL ELECTRIC 190
19.2.1 COMPANY SNAPSHOT 190
19.2.2 REVENUE ANALYSIS 190
19.2.3 COMPANY SHARE ANALYSIS 191
19.2.4 PRODUCT PORTFOLIO 191
19.2.5 RECENT DEVELOPMENT 191
19.3 ABBOTT 192
19.3.1 COMPANY SNAPSHOT 192
19.3.2 REVENUE ANALYSIS 192
19.3.3 COMPANY SHARE ANALYSIS 193
19.3.4 PRODUCT PORTFOLIO 193
19.3.5 RECENT DEVELOPMENT 193
19.4 QIAGEN 194
19.4.1 COMPANY SNAPSHOT 194
19.4.2 REVENUE ANALYSIS 194
19.4.3 COMPANY SHARE ANALYSIS 195
19.4.4 PRODUCT PORTFOLIO 195
19.4.5 RECENT DEVELOPMENT 195
19.5 MYRIAD GENETICS, INC. 196
19.5.1 COMPANY SNAPSHOT 196
19.5.2 REVENUE ANALYSIS 196
19.5.3 COMPANY SHARE ANALYSIS 197
19.5.4 PRODUCT PORTFOLIO 197
19.5.5 RECENT DEVELOPMENT 197
19.6 ACON LABORATORIES, INC. 198
19.6.1 COMPANY SNAPSHOT 198
19.6.2 PRODUCT PORTFOLIO 198
19.6.3 RECENT DEVELOPMENT 198
19.7 ADVACARE PHARMA 199
19.7.1 COMPANY SNAPSHOT 199
19.7.2 PRODUCT PORTFOLIO 199
19.7.3 RECENT DEVELOPMENT 199
19.8 AGILENT TECHNOLOGIES, INC. 200
19.8.1 COMPANY SNAPSHOT 200
19.8.2 REVENUE ANALYSIS 200
19.8.3 PRODUCT PORTFOLIO 201
19.8.4 RECENT DEVELOPMENTS 201
19.9 BIOMRIEUX 202
19.9.1 COMPANY SNAPSHOT 202
19.9.2 REVENUE ANALYSIS 202
19.9.3 PRODUCT PORTFOLIO 203
19.9.4 RECENT DEVELOPMENT 203
19.10 BIOCEPT, INC. 204
19.10.1 COMPANY SNAPSHOT 204
19.10.2 REVENUE ANALYSIS 204
19.10.3 PRODUCT PORTFOLIO 205
19.10.4 RECENT DEVELOPMENT 205
19.11 BIOHIT OYJ 206
19.11.1 COMPANY SNAPSHOT 206
19.11.2 REVENUE ANALYSIS 206
19.11.3 PRODUCT PORTFOLIO 207
19.11.4 RECENT DEVELOPMENT 207
19.12 DIASORIN S.P.A 208
19.12.1 COMPANY SNAPSHOT 208
19.12.2 REVENUE ANALYSIS 208
19.12.3 PRODUCT PORTFOLIO 209
19.12.4 RECENT DEVELOPMENT 209
19.13 ENDOFOTONICS PTE LTD 210
19.13.1 COMPANY SNAPSHOT 210
19.13.2 PRODUCT PORTFOLIO 210
19.13.3 RECENT DEVELOPMENT 210
19.14 FOUNDATION MEDICINE, INC. 211
19.14.1 COMPANY SNAPSHOT 211
19.14.2 PRODUCT PORTFOLIO 211
19.14.3 RECENT DEVELOPMENTS 211
19.15 FUJIREBIO (AN H.U. GROUP COMPANY) 212
19.15.1 COMPANY SNAPSHOT 212
19.15.2 REVENUE ANALYSIS 212
19.15.3 PRODUCT PORTFOLIO 213
19.15.4 RECENT DEVELOPMENT 213
19.16 MIRXES PTE LTD. 214
19.16.1 COMPANY SNAPSHOT 214
19.16.2 PRODUCT PORTFOLIO 214
19.16.3 RECENT DEVELOPMENT 214
19.17 PARAGON GENOMICS, INC. 215
19.17.1 COMPANY SNAPSHOT 215
19.17.2 PRODUCT PORTFOLIO 215
19.17.3 RECENT DEVELOPMENTS 215
19.18 TECO DIAGNOSTICS 216
19.18.1 COMPANY SNAPSHOT 216
19.18.2 PRODUCT PORTFOLIO 216
19.18.3 RECENT DEVELOPMENT 216
19.19 THERMO FISHER SCIENTIFIC INC. 217
19.19.1 COMPANY SNAPSHOT 217
19.19.2 REVENUE ANALYSIS 217
19.19.3 PRODUCT PORTFOLIO 218
19.19.4 RECENT DEVELOPMENTS 218
19.20 VELA DIAGNOSTICS 219
19.20.1 COMPANY SNAPSHOT 219
19.20.2 PRODUCT PORTFOLIO 219
19.20.3 RECENT DEVELOPMENTS 219
20 QUESTIONNAIRE 220
21 RELATED REPORTS 225

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.